Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Journey Program In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25% weight loss) INDIANAPOLIS , June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program.1 Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less ($349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.
![]() LLY In 2 months Estimated | Quarterly | $1.5 Per Share |
![]() LLY 1 month ago Paid | Quarterly | $1.5 Per Share |
![]() LLY 4 months ago Paid | Quarterly | $1.5 Per Share |
![]() LLY 7 months ago Paid | Quarterly | $1.3 Per Share |
![]() LLY 10 months ago Paid | Quarterly | $1.3 Per Share |
![]() LLY 15 May 2024 Paid | Quarterly | $1.3 Per Share |
28 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 5.07 Cons. EPS | 5.32 EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | 1.47 Cons. EPS | 1.18 EPS |
8 Aug 2024 Date | | 2.6 Cons. EPS | 3.92 EPS |
![]() LLY In 2 months Estimated | Quarterly | $1.5 Per Share |
![]() LLY 1 month ago Paid | Quarterly | $1.5 Per Share |
![]() LLY 4 months ago Paid | Quarterly | $1.5 Per Share |
![]() LLY 7 months ago Paid | Quarterly | $1.3 Per Share |
![]() LLY 10 months ago Paid | Quarterly | $1.3 Per Share |
![]() LLY 15 May 2024 Paid | Quarterly | $1.3 Per Share |
28 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 5.07 Cons. EPS | 5.32 EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | 1.47 Cons. EPS | 1.18 EPS |
8 Aug 2024 Date | | 2.6 Cons. EPS | 3.92 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. David A. Ricks CEO | BVL Exchange | US5324571083 ISIN |
US Country | 47,000 Employees | 14 Feb 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.